TY - JOUR
T1 - Radiotherapy Combined with Daily Administration of Low Dose Cisplatin for Head and Neck Cancer — Studies on Serum Concentrations of Cisplatin and Acute Complications —
AU - Fujita, Masahiro
AU - Masaki, Norie
AU - Murayama, Shigeyuki
AU - Matayoshi, Yoshinobu
AU - Ikeda, Hiroshi
AU - Shimizutani, Kimishige
AU - Inoue, Toshihiko
AU - Kozuka, Takahiro
PY - 1990/1
Y1 - 1990/1
N2 - Serum concentrations of cisplatin (CDDP) and acute complications were studied in patients treated for head and neck cancer by radiotherapy combined with daily administration of low doses of CDDP (5 mg/m2 or 6 mg/body) at Osaka University Hospital between March 1988 and December 1989. Serum concentrations of total-CDDP (6 patients) and free-CDDP (2 patients) were studied in cases injected intravenously with 5 mg/m2 daily. Total-CDDP determined just before daily administration of CDDP was increased gradually (0.35 to 0.64 μg/ml by the 7th day, 0.42 to 0.91 μg/ml by the 14th day and 0.60 to 0.82 μg/m/ by the 20 or 21st day) and still observed in the serum for more than two weeks after cessation of the chemotherapy. Serum concentrations of free-CDDP were about 0.35 μg/ml at 5 minutes and 0.15 μg/ml at 30 minutes after the intravenous injection of CDDP. Incidence of the acute complications more severe than grade 2 were nausea and vomiting: 4/52 (8%), leukopenia: 11/52 (21%) and thrombocytopenia: 4/52 (8%), Incidence of myelosuppression (leukopenia and/or thrombocytopenia) was 11/26 (42%) when the total dose of CDDP exceeded 120 mg, and 3/26 (12%) when it was less than 120 mg. Transient renal dysfunction (increase of serum creatinine) of grade 1 was seen in only 3 patients.
AB - Serum concentrations of cisplatin (CDDP) and acute complications were studied in patients treated for head and neck cancer by radiotherapy combined with daily administration of low doses of CDDP (5 mg/m2 or 6 mg/body) at Osaka University Hospital between March 1988 and December 1989. Serum concentrations of total-CDDP (6 patients) and free-CDDP (2 patients) were studied in cases injected intravenously with 5 mg/m2 daily. Total-CDDP determined just before daily administration of CDDP was increased gradually (0.35 to 0.64 μg/ml by the 7th day, 0.42 to 0.91 μg/ml by the 14th day and 0.60 to 0.82 μg/m/ by the 20 or 21st day) and still observed in the serum for more than two weeks after cessation of the chemotherapy. Serum concentrations of free-CDDP were about 0.35 μg/ml at 5 minutes and 0.15 μg/ml at 30 minutes after the intravenous injection of CDDP. Incidence of the acute complications more severe than grade 2 were nausea and vomiting: 4/52 (8%), leukopenia: 11/52 (21%) and thrombocytopenia: 4/52 (8%), Incidence of myelosuppression (leukopenia and/or thrombocytopenia) was 11/26 (42%) when the total dose of CDDP exceeded 120 mg, and 3/26 (12%) when it was less than 120 mg. Transient renal dysfunction (increase of serum creatinine) of grade 1 was seen in only 3 patients.
KW - Acute complications
KW - Chemotherapy
KW - Cisplatin
KW - Head and neck cancer
KW - Radiotherapy
KW - Serum concentrations
UR - http://www.scopus.com/inward/record.url?scp=84996027216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996027216&partnerID=8YFLogxK
U2 - 10.11182/jastro1989.2.255
DO - 10.11182/jastro1989.2.255
M3 - Article
AN - SCOPUS:84996027216
SN - 1040-9564
VL - 2
SP - 255
EP - 262
JO - The Journal of JASTRO
JF - The Journal of JASTRO
IS - 4
ER -